Antithrombotic therapy after acute coronary syndrome and/or percutaneous coronary intervention in atrial fibrillation: finding the sweet spot

Eur Heart J. 2019 Dec 7;40(46):3768-3770. doi: 10.1093/eurheartj/ehz823.

Authors

Renato D Lopes^{1

2}, Hwanhee Hong^{2

3}, John H Alexander^{1

2}

Affiliations

¹ Division of Cardiology, Duke University School of Medicine, Durham, NC, USA.
² Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
³ Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA.

PMID: 31774111
DOI: 10.1093/eurheartj/ehz823

No abstract available

Publication types

Editorial
Comment

MeSH terms

Acute Coronary Syndrome*
Anticoagulants
Atrial Fibrillation*
Fibrinolytic Agents
Humans
Percutaneous Coronary Intervention*
Randomized Controlled Trials as Topic

Substances

Anticoagulants
Fibrinolytic Agents